MedTrace Logo

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

NCT07413666 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2026-02-25

No results posted yet for this study

Summary

Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.

Conditions

  • Healthy Adult Male and Female Volunteers

Interventions

DRUG

ORX489 Tablets

ORX489 Tablets

OTHER

Placebo Tablets

Placebo Tablets

Sponsors & Collaborators

  • Centessa Pharmaceuticals (UK) Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-25
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07413666 on ClinicalTrials.gov